Vismodegib
- Generic Name
- Vismodegib
- Brand Names
- Erivedge
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14Cl2N2O3S
- CAS Number
- 879085-55-9
- Unique Ingredient Identifier
- 25X868M3DS
- Background
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling p...
- Indication
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
- Associated Therapies
- -
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT02648048
- Locations
- 🇺🇸
Tulane University Medical School, New Orleans, Louisiana, United States
🇺🇸Suburban Lung Associates, Elk Grove, Illinois, United States
🇺🇸Allied Clinical Research, Reno, Nevada, United States
Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 4
- Registration Number
- NCT02639117
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT02593760
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸Oncology Hematology Care Inc, Cincinnati, Ohio, United States
🇺🇸Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers, Florida, United States
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Conditions
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 124
- Registration Number
- NCT02523014
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Breast, Grosse Pointe Woods, Michigan, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Interventions
- Drug: AfatinibDrug: CapivasertibDrug: BinimetinibDrug: AdavosertibProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: Afatinib DimaleateDrug: DabrafenibDrug: DefactinibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: TaselisibDrug: SapanisertibDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: UlixertinibBiological: Trastuzumab EmtansineDrug: Copanlisib HydrochlorideBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabDrug: Larotrectinib SulfateOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
VISmodegib for ORbital and Periocular Basal Cell Carcinoma
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT02436408
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02371967
- Locations
- 🇸🇪
Skånes Universitetssjukhus; Hudkliniken, Lund, Sweden
🇸🇪SU/Sahlgrenska, Hudkliniken, Göteborg, Sweden
🇸🇪Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden
A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- NYU College of Dentistry
- Target Recruit Count
- 2
- Registration Number
- NCT02366312
- Locations
- 🇺🇸
NYU Bluestone Center For Cllinical Research, New York, New York, United States
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT02337517
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02168530
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.